Rocket Pharmaceuticals develops gene therapies for rare inherited heart diseases. RCKT reports earnings on Thu, Nov 5, 2026. Analyst consensus is Buy, based on the latest ratings from 5 firms (3 buy, 2 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 8 | Goldman Sachs | Upgrade | Hold | |
| Oct 7 | Leerink Partners | Maintained | Hold | |
| Sep 16 | Wedbush | Reiterated | Buy | |
| Sep 16 | Needham | Upgrade | Buy | |
| Sep 1 | Chardan Capital | Maintained | Buy |
Seasonality
How RCKT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.
Whale Options Flow
90DNo whale options trades in RCKT in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RCKT is in one of them and how their past RCKT trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered RCKT in an article yet. Here's the latest on the wider market.
About Rocket Pharmaceuticals
Rocket Pharmaceuticals is a biotechnology company based in New York that develops gene therapies for rare inherited diseases. Its main focus is heart conditions caused by genetic mutations, such as certain forms of cardiomyopathy. The company uses modified viruses that do not cause disease to deliver working copies of genes into patients' cells. Its treatments are aimed at patients with rare conditions, and the company works with healthcare providers, payors and patient communities.
- Headquarters
- New York, NY